Five months after President Trump called TrumpRx.gov “the biggest thing to happen in healthcare in decades,” an NPR analysis has found that the site’s much-publicized deals cover fewer than 12% of the more than 800 brand-name drugs made by the 17 pharmaceutical companies that signed on.
The platform that was supposed to be a supermarket for cheaper medicine is operating more like a boutique.
The Numbers Behind the Marketing
As of mid-July, TrumpRx lists 92 brand-name drug deals from 15 of the 17 companies that announced agreements with the administration. That means two companies have not put a single drug on the platform despite the splashy White House announcements, and the other 15 are offering only a selective slice of their portfolios.
Pfizer leads the pack with 30 drugs listed, the most of any company on the site. But Pfizer makes at least 178 brand-name drugs currently on the market. That means roughly 83% of Pfizer’s portfolio is not available through TrumpRx. And the exclusions are not obscure specialty treatments. NPR’s analysis found that Eliquis, a widely prescribed blood thinner, Ibrance for advanced and metastatic breast cancer, and Paxlovid, the COVID treatment, are all absent from the platform.
“The key takeaway is that most of these companies are doing this for a small number of products and in a limited setting,” Dr. Ben Rome, a health policy researcher at Brigham and Women’s Hospital in Boston, told NPR. “They’re not engaging to do this on a large scale.”
Why Drug Companies Are Playing Along (Selectively)
The structural why here is not generosity. The pharmaceutical industry agreed to these deals in exchange for a reprieve from tariffs. That is a straightforward trade: offer discounts on a curated list of drugs the company was willing to discount anyway, and avoid tariffs that would hit the entire product line. The companies get to claim participation in a presidential initiative while controlling exactly which products get cheaper and which stay at full price.
The site has found its most visible use case with GLP-1 drugs, the weight-loss and diabetes medications that have become among the most-prescribed drugs in the country. For patients who need those specific medications, TrumpRx has delivered real savings. But a separate NPR analysis found that the platform’s coverage gaps leave entire treatment categories uncovered, including treatments for inflammatory conditions, HIV, and many cancers.
The Gap Between the Announcement and the Reality
When TrumpRx launched in February, the White House framed it as a mechanism to bring American drug prices in line with the lowest paid by other developed nations, the so-called most-favored-nation price. The site also added more than 600 generic medications, which are already available at low cost through existing pharmacy programs. The generics pad the numbers without meaningfully expanding access.
Drug policy experts have been cautious in their assessments. The consensus is that TrumpRx will help a limited number of patients with specific conditions, primarily those taking GLP-1s, while doing little for the broader population that depends on brand-name drugs excluded from the deals. That is not nothing. But it is a long way from the promise of a healthcare revolution.
The administration continues to trumpet the deals as evidence that it is delivering lower drug prices. The pharmaceutical companies continue to participate on their own terms. And the patients whose medications are not on the list continue to pay full price, tariff reprieve or not.
That gap between the announcement and the reality is the actual story of TrumpRx six months in. The question is whether the administration will push for broader coverage or settle for a showcase that works for the drugs companies were already willing to discount.